866-997-4948(US-Canada Toll Free)

Oncology Biosimilars Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2022

Published By :

Transparency Market Research

Published Date : Sep 2017

Category :

Pharmaceutical

No. of Pages : 183 Pages

Global Oncology Biosimilars Market: Overview

This report on the oncology biosimilars market analyzes the current and future scenario of the global market. Increasing prevalence of cancer, innovation in the development of new drugs, pipeline analysis, and drug class sales during the forecast period.

The global oncology biosimilars market report contain an elaborate executive summary, which includes following points such as market snapshot that provides information about various segments globally. It also comprise information and data analysis of the country’s market with respect to the segments based on drug class, disease indication, distribution channels and regions. A detailed qualitative analysis of drivers and restraints, opportunities, and trends has been provided in the market overview section. Additionally, the section comprises key molecules, Porters Five Forces Analysis and cancer statistics to help understand the competitive landscape in the market. This section also provides market attractiveness analysis in terms of country and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global oncology biosimilars market.

Global Oncology Biosimilars Market: Market Segmentation

Based on drug class, the market has been segmented into three major drug class such as G-CSF, monoclonal antibody, hematopoietic agents. The market segments have been analyzed based on available approved products, cost-effectiveness. All segments market size and forecast has been presented for the period from 2017 to 2025, 2016 consider as a base year for this report.

In terms of disease indication – the oncology biosimilars market has been segmented into following segments including breast cancer, non-small cell lung cancer, colorectal cancer, neutropenia, blood cancer and others. . All segments market size and forecast has been presented for the period from 2017 to 2025, 2016 consider as a base year for this report.

As per distribution channels, the oncology biosimilars market has been segmented into three segments including hospital pharmacy, retail pharmacy, and online pharmacy. All market segmentations has been analyzed based on increasing demand for disease treatment. Increased patient hospitalization for the treatment of cancer are driving the market share of hospital pharmacy segment. The market size and forecast in terms of US$ Mn for each segment have been provided for the period from 2015 to 2025. The report also comprise the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2017 to 2025, considering 2016 as the base year.

Geographically, oncology biosimilars market on the basis of region has been segmented into North America, Europe, Asia Pacific and Rest of the World. The market size and forecast for each of these regions have been presented for the period from 2015 to 2025. CAGR for all segments has been presented for the period from 2017 to 2025, 2016 consider as a base year for this report. The report also profiles major key players in the oncology biosimilars market based on various attributes such as company overview, product portfolio, financial overview, business strategies, recent developments and company SWOT analysis.

Global Oncology Biosimilars Market: Competitive Dynamics

Key players for oncology biosimilars market profiled in this report are Celltrion Inc., Pfizer, Inc., Biocon, Sandoz International GmbH (A Novartis Division), Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., STADA Arzneimittel AG, Apotex Inc. (Apobiologix), Intas Pharmaceuticals Ltd. And BIOCAD.

The Oncology Biosimilars Market has been segmented as follows:

  • Oncology Biosimilars Market, by Drug Class, Revenue (US$ Mn) 2015-2025
    • G-CSF
    • mAb
    • Hematopoetic Agents
       
  • Oncology Biosimilars Market, by Disease Indication, Revenue (US$ Mn) 2015-2025
    • Breast Cancer
    • Non-Small Cell Lung Cancer
    • Blood Cancer
      • Leukemia
        • Myeloid Leukemia
        • CLL
        • Others
      • Non-Hodgkin's Lymphoma
    • Colorectal Cancer
    • Neutropenia
    • Others
       
  • Oncology Biosimilars Market, by Distribution Channel, Revenue (US$ Mn) 2015-2025
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • Oncology Biosimilars Market Revenue, by Geography (US$ Bn), 2015-2025
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • France
      • U.K.
      • Italy
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • Japan
      • China
      • India
      • Australia & New Zealand
      • Rest of Asia Pacific
    • Rest of the World
      • Mexico
      • Brazil
      • Rest of ROW

Section 01 Preface
1.1 Market Definition and Scope
1.2 Research Highlights

Section 02 Assumptions and Research Methodology
2.1 Assumptions & Acronyms Used
2.2 Research Methodology

Section 03 Executive Summary: Global Oncology Biosimilars Market
3.1 Executive Summary
3.2 Market Opportunity Map
3.3 Market Overview
3.4 Key Industry Developments
3.5 Global Oncology Biosimilars Market Size (US$ Mn) Forecast, 2015–2025
3.6 Global Oncology Biosimilars Market Outlook

Section 04 Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunity
4.4 Key Trends

Section 05 Porter’s Five Force Analysis

Section 06 Oncology Biosimilars: Key Molecules

Section 07 Biosimilars Market Snapshot

Section 08 Cancer Statistics

Section 09 Global Oncology Biosimilars Market Analysis and Forecasts, By Drug Class 
9.1 Introduction & Definition
9.2 Key Findings 
9.3 Global Oncology Biosimilars Market Value Share, by Drug Class, 2017 and 2025
9.4 Market Attractiveness By Drug Class 
9.5 Global Oncology Biosimilars Market Forecast, by Drug Class, 2015-2025
      9.5.1 G-CSF
      9.5.2 Monoclonal Antibody
      9.5.3 Hematopoietic Agents
9.6 Global Oncology Biosimilars Market Analysis, by Drug Class, 2015-2025
9.7 Key Trends

Section 10 Global Oncology Biosimilars Market Analysis and Forecasts, By Disease Indication 
10.1 Introduction & Definition
10.2 Key Findings 
10.3 Global Oncology Biosimilars Market Value Share, by Disease Indication, 2017 and 2025
10.4 Market Attractiveness By Disease Indication
10.5 Global Oncology Biosimilars Market Forecast, by Disease Indication, 2015-2025
      10.5.1 Breast Cancer
      10.5.2 Non-Small Cell lung Cancer
      10.5.3 Blood Cancer
               10.5.3.1 Leukemia
                          10.5.3.1.1 Myeloid Leukemia
                          10.5.3.1.2 Chronic Lymphocytic Leukemia
                          10.5.3.1.3 Others
               10.5.3.2 Non-Hodgkin Lymphoma
      10.5.4 Colorectal Cancer
      10.5.5 Neutropenia
      10.5.6 Others
10.6 Global Oncology Biosimilars Market Analysis, by Disease Indication, 2015-2025
10.7 Key Trends

Section 11 Global Oncology Biosimilars Market Analysis and Forecasts, By Distribution Channel 
11.1 Introduction & Definition
11.2 Key Findings 
11.3 Global Oncology Biosimilars Market Value Share, by Distribution Channel, 2017 and 2025
11.4 Market Attractiveness By Distribution Channel
11.5 Global Oncology Biosimilars Market Forecast, by Distribution Channel, 2015-2025
      11.5.1 Hospital Pharmacy
      11.5.2 Online Pharmacy
      11.5.3 Retail Pharmacy
11.6 Global Oncology Biosimilars Market Analysis, by Distribution Channel, 2015-2025
11.7 Key Trends

Section 12 Global Oncology Biosimilars Market Analysis and Forecasts, By Region
12.1 Global Market Scenario
12.2 Global Oncology Biosimilars Market Value Share, by Region, 2017 and 2025
12.3 Global Oncology Biosimilars Market Attractiveness, by Region, 2017–2025
12.4 Global Oncology Biosimilars Market Size (US$ Mn) Forecast, by Region, 2015–2025
      12.4.1 North America 
      12.4.2 Europe 
      12.4.3 Asia Pacific 
      12.4.4 Rest of the World 

Section 13 North America Oncology Biosimilars Market Analysis and Forecast
13.1 North America Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2015–2025
13.2 North America Oncology Biosimilars Market Value Share, by Country, 2017 and 2025
13.3 North America Oncology Biosimilars Market Attractiveness, by Country, 2017–2025
13.4 North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2015–2025
      13.4.1 U.S.
      13.4.2 Canada
13.5 North America Oncology Biosimilars Market Value Share, by Drug Class, 2017 and 2025
13.6 North America Oncology Biosimilars Market Attractiveness, by Drug Class, 2017–2025
13.7 North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
      13.7.1 G-CSF
      13.7.2 Monoclonal Antibody
      13.7.3 Hematopoietic Agents
13.8 North America Oncology Biosimilars Market Value Share, by Disease Indication, 2017 and 2025
13.9 North America Oncology Biosimilars Market Attractiveness, by Disease Indication, 2017–2025
13.10 North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
      13.10.1 Breast Cancer
      13.10.2 Non-Small Cell lung Cancer
      13.10.3 Blood Cancer
               13.10.3.1 Leukemia
                          13.10.3.1.1 Myeloid Leukemia
                          13.10.3.1.2 Chronic Lymphocytic Leukemia
                          13.10.3.1.3 Others
               13.10.3.2 Non-Hodgkin Lymphoma
      13.10.4 Colorectal Cancer
      13.10.5 Neutropenia
      13.10.6 Others
13.11 North America Oncology Biosimilars Market Value Share, by Distribution Channel, 2017 and 2025
13.12 North America Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2017–2025
13.13 North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
      13.13.1 Hospital Pharmacy
      13.13.2 Online Pharmacy
      13.13.3 Retail Pharmacy
13.14 Key Trends

Section 14 Europe Oncology Biosimilars Market Analysis and Forecast
14.1 Europe Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2015–2025
14.2 Europe Oncology Biosimilars Market Value Share, by Country, 2017 and 2025
14.3 Europe Oncology Biosimilars Market Attractiveness, by Country, 2017–2025
14.4 Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2015–2025
      14.4.1 U.K.
      14.4.2 Germany
      14.4.3 France
      14.4.4 Italy
      14.4.5 Russia
      14.4.6 Spain
      14.4.7 Rest of Europe
14.5 Europe Oncology Biosimilars Market Value Share, by Drug Class, 2017 and 2025
14.6 Europe Oncology Biosimilars Market Attractiveness, by Drug Class, 2017–2025
14.7 Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
      14.7.1 G-CSF
      14.7.2 Monoclonal Antibody
      14.7.3 Hematopoietic Agents
14.8 Europe Oncology Biosimilars Market Value Share, by Disease Indication, 2017 and 2025
14.9 Europe Oncology Biosimilars Market Attractiveness, by Disease Indication, 2017–2025
14.10 Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
      14.10.1 Breast Cancer
      14.10.2 Non-Small Cell lung Cancer
      14.10.3 Blood Cancer
               14.10.3.1 Leukemia
                          14.10.3.1.1 Myeloid Leukemia
                          14.10.3.1.2 Chronic Lymphocytic Leukemia
                          14.10.3.1.3 Others
               14.10.3.2 Non-Hodgkin Lymphoma
      14.10.4 Colorectal Cancer
      14.10.5 Neutropenia
      14.10.6 Others
14.11 Europe Oncology Biosimilars Market Value Share, by Distribution Channel, 2017 and 2025
14.12 Europe Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2017–2025
14.13 Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
      14.13.1 Hospital Pharmacy
      14.13.2 Online Pharmacy
      14.13.3 Retail Pharmacy
14.14 Key Trends

Section 15 Asia Pacific Oncology Biosimilars Market Analysis and Forecast
15.1 Asia Pacific Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2015–2025
15.2 Asia Pacific Oncology Biosimilars Market Value Share, by Country, 2017 and 2025
15.3 Asia Pacific Oncology Biosimilars Market Attractiveness, by Country, 2017–2025
15.4 Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2015–2025
      15.4.1 China
      15.4.2 India
      15.4.3 Japan
      15.4.4 Australia & New Zealand
      15.4.5 Rest of Asia Pacific
15.5 Asia Pacific Oncology Biosimilars Market Value Share, by Drug Class, 2017 and 2025
15.6 Asia Pacific Oncology Biosimilars Market Attractiveness, by Drug Class, 2017–2025
15.7 Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
      15.7.1 G-CSF
      15.7.2 Monoclonal Antibody
      15.7.3 Hematopoietic Agents
15.8 Asia Pacific Oncology Biosimilars Market Value Share, by Disease Indication, 2017 and 2025
15.9 Asia Pacific Oncology Biosimilars Market Attractiveness, by Disease Indication, 2017–2025
15.10 Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
      15.10.1 Breast Cancer
      15.10.2 Non-Small Cell lung Cancer
      15.10.3 Blood Cancer
               15.10.3.1 Leukemia
                          15.10.3.1.1 Myeloid Leukemia
                          15.10.3.1.2 Chronic Lymphocytic Leukemia
                          15.10.3.1.3 Others
               15.10.3.2 Non-Hodgkin Lymphoma
      15.10.4 Colorectal Cancer
      15.10.5 Neutropenia
      15.10.6 Others
15.11 Asia Pacific Oncology Biosimilars Market Value Share, by Distribution Channel, 2017 and 2025
15.12 Asia Pacific Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2017–2025
15.13 Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
      15.13.1 Hospital Pharmacy
      15.13.2 Online Pharmacy
      15.13.3 Retail Pharmacy
15.14 Key Trends

Section 16 Rest of the World Oncology Biosimilars Market Analysis and Forecast
16.1 Rest of the World Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2015–2025
16.2 Rest of the World Oncology Biosimilars Market Value Share, by Country, 2017 and 2025
16.3 Rest of the World Oncology Biosimilars Market Attractiveness, by Country, 2017–2025
16.4 Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2015–2025
      16.4.1 Mexico
      16.4.2 Brazil
      16.4.3 Rest of the World
16.5 Rest of the World Oncology Biosimilars Market Value Share, by Drug Class, 2017 and 2025
16.6 Rest of the World Oncology Biosimilars Market Attractiveness, by Drug Class, 2017–2025
16.7 Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
      16.7.1 G-CSF
      16.7.2 Monoclonal Antibody
      16.7.3 Hematopoietic Agents
16.8 Rest of the World Oncology Biosimilars Market Value Share, by Disease Indication, 2017 and 2025
16.9 Rest of the World Oncology Biosimilars Market Attractiveness, by Disease Indication, 2017–2025
16.10 Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
      16.10.1 Breast Cancer
      16.10.2 Non-Small Cell lung Cancer
      16.10.3 Blood Cancer
                16.10.3.1 Leukemia
                          16.10.3.1.1 Myeloid Leukemia
                          16.10.3.1.2 Chronic Lymphocytic Leukemia
                          16.10.3.1.3 Others
                16.10.3.2 Non-Hodgkin Lymphoma
      16.10.4 Colorectal Cancer
      16.10.5 Neutropenia
      16.10.6 Others
16.11 Rest of the World Oncology Biosimilars Market Value Share, by Distribution Channel, 2017 and 2025
16.12 Rest of the World Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2017–2025
16.13 Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
      16.13.1 Hospital Pharmacy
      16.13.2 Online Pharmacy
      16.13.3 Retail Pharmacy
16.14 Key Trends

Section 17 Competition Landscape
17.1 Market Player – Competition Matrix (By Tier and Size of companies)
17.2 Market Share Analysis By Company (2016)

Section 18 Company Profiles
18.1 Sandoz International GmbH
      18.1.1 Company Details
      18.1.2 Business Overview
      18.1.3 Financial Overview
      18.1.4 Strategic Overview
      18.1.5 SWOT Analysis
18.2 Pfizer, Inc.
      18.2.1 Company Details
      18.2.2 Business Overview
      18.2.3 Financial Overview
      18.2.4 Strategic Overview
      18.2.5 SWOT Analysis
18.3 Celltrion Inc.
      18.3.1 Company Details
      18.3.2 Business Overview
      18.3.3 Financial Overview
      18.3.4 Strategic Overview
      18.3.5 SWOT Analysis
18.4 Dr. Reddy’s Laboratories Ltd.
      18.4.1 Company Details
      18.4.2 Business Overview
      18.4.3 Financial Overview
      18.4.4 Strategic Overview
      18.4.5 SWOT Analysis
18.5 Biocon
      18.5.1 Company Details
      18.5.2 Business Overview
      18.5.3 Financial Overview
      18.5.4 Strategic Overview
      18.5.5 SWOT Analysis
18.6 Teva Pharmaceutical Industries Ltd.
      18.6.1 Company Details
      18.6.2 Business Overview
      18.6.3 Financial Overview
      18.6.4 Strategic Overview
      18.6.5 SWOT Analysis
18.7 STADA Arzneimittel AG
      18.7.1 Company Details
      18.7.2 Business Overview
      18.7.3 Financial Overview
      18.7.4 Strategic Overview
      18.7.5 SWOT Analysis
18.8 Apotex Inc. (Apobiologix)
      18.8.1 Company Details
      18.8.2 Business Overview
      18.8.3 Financial Overview
      18.8.4 Strategic Overview
      18.8.5 SWOT Analysis
18.9 Intas Pharmaceuticals Ltd.
      18.9.1 Company Details
      18.9.2 Business Overview
      18.9.3 Financial Overview
      18.9.4 Strategic Overview
      18.9.5 SWOT Analysis
18.10 BIOCAD
      18.10.1 Company Details
      18.10.2 Business Overview
      18.10.3 Financial Overview
      18.10.4 Strategic Overview
      18.10.5 SWOT Analysis

List of Table

List of Tables

Table 01 Global Biosimilars Market Snapshot
Table 02 Global Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 03 Global Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 04 Global Oncology Biosimilars Market Size (US$ Mn) Forecast, Blood Cancer, 2015–2025
Table 05 Global Oncology Biosimilars Market Size (US$ Mn) Forecast, by Leukemia, 2015–2025
Table 06 Global Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 07 Global Oncology Biosimilars Market Size (US$ Mn) Forecast, by Region, 2015–2025
Table 08 Approved Oncology Biosimilars by USFDA in new biosimilars pathway established under BPCIA Act
Table 09 North America Oncology Biosimilars: Pipeline Overview, 2017-2020
Table 10 North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 11 North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 12 Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 13 Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 14 Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 15 Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Blood Cancer, 2015–2025
Table 16 Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Leukemia, 2015–2025
Table 17 Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 18 Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 19 Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 20 Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 21 Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Blood Cancer, 2015–2025
Table 22 Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Leukemia, 2015–2025
Table 23 Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 24 Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 25 Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, Drug Class, 2015–2025
Table 26 Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 27 Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Blood Cancer, 2015–2025
Table 28 Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Leukemia, 2015–2025
Table 29 Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025

List of Chart

List of Figures


Fig. 01 Global Oncology Biosimilars Market Size (US$ Mn) Forecast, 2015–2025

Fig. 02 Global Oncology Biosimilars Market Value Share, by Drug Class (2016)

Fig. 03 Global Oncology Biosimilars Market Value Share, by Disease Indication (2016)

Fig. 04 Global Oncology Biosimilars Market Value Share, by Distribution Channel (2016)

Fig. 05 Global Oncology Biosimilars Market Value Share, by Region (2016)

Fig. 06 U.S. Prevalence Share (%), By Cancer Type, 2015

Fig. 07 Global Estimation of Cancer, By New Cases & Deaths, 2017 

Fig. 08 Global Oncology Biosimilars Market Value Share, by Drug Class, 2017 and 2025

Fig. 09 Global Oncology Biosimilars Market Attractiveness, by Drug Class, 2017–2025

Fig. 10 Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Monoclonal Antibody, 2015–2025

Fig. 11 Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Hematopoietic Agents, 2015–2025

Fig. 12 Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by G-CSF, 2015–2025

Fig. 13 Global Oncology Biosimilars Market Value Share, by Disease Indication, 2017 and 2025

Fig. 14 Global Oncology Biosimilars Market Attractiveness, by Disease Indication, 2017–2025

Fig. 15 Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Breast Cancer, 2015–2025

Fig. 16 Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Non-small Cell Lung Cancer, 2015–2025

Fig. 17 Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Blood Cancer, 2015–2025

Fig. 18 Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Colorectal Cancer, 2015–2025

Fig. 19 Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Neutropenia, 2015–2025

Fig. 20 Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Others, 2015–2025

Fig. 21 Global Oncology Biosimilars Market Value Share, by Distribution Channel, 2017 and 2025

Fig. 22 Global Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2017–2025

Fig. 23 Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Online Pharmacy, 2015–2025

Fig. 24 Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Retail Pharmacy, 2015–2025

Fig. 25 Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Hospital Pharmacy, 2015–2025

Fig. 26 Global Oncology Biosimilars Market Value Share, by Region, 2017 and 2025 

Fig. 27 Global Oncology Biosimilars Market Attractiveness, by Region, 2017–2025

Fig. 28 North America Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2015–2025

Fig. 29 North America Oncology Biosimilars Market Value Share, by Country, 2017 and 2025 

Fig. 30 North America Oncology Biosimilars Market Attractiveness, by Country, 2017–2025

Fig. 31 North America Oncology Biosimilars Market Value Share, by Distribution Channel, 2017 and 2025

Fig. 32 North America Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2017–2025

Fig. 33 Europe Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2015–2025

Fig. 34 Europe Oncology Biosimilars Market Value Share, by Country, 2017 and 2025 

Fig. 35 Europe Oncology Biosimilars Market Attractiveness, by Country, 2017–2025

Fig. 36 Europe Oncology Biosimilars Market Value Share, by Drug Class, 2017 and 2025

Fig. 37 Europe Oncology Biosimilars Market Attractiveness, by Drug Class, 2017–2025

Fig. 38 Europe Oncology Biosimilars Market Value Share, by Disease Indication, 2017 and 2025

Fig. 39 Europe Oncology Biosimilars Market Attractiveness, by Disease Indication, 2017–2025

Fig. 40 Europe Oncology Biosimilars Market Value Share, by Distribution Channel, 2017 and 2025

Fig. 41 Europe Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2017–2025

Fig. 42 Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015–2025

Fig. 43 Asia Pacific Oncology Biosimilars Market Value Share, by Country, 2017 and 2025 

Fig. 44 Asia Pacific Oncology Biosimilars, Market Attractiveness, by Country, 2017–2025

Fig. 45 Asia Pacific Oncology Biosimilars Market Value Share, by Drug Class, 2017 and 2025

Fig. 46 Asia Pacific Oncology Biosimilars Market Attractiveness, by Drug Class, 2017–2025

Fig. 47 Asia Pacific Oncology Biosimilars Market Value Share, by Disease Indication, 2017 and 2025

Fig. 48 Asia Pacific Oncology Biosimilars Market Attractiveness, by Disease Indication, 2017–2025

Fig. 49 Asia Pacific Oncology Biosimilars Market Value Share, by Distribution Channel, 2017 and 2025

Fig. 50 Asia Pacific Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2017–2025

Fig. 51 Rest of the World Oncology Biosimilars, Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015–2025

Fig. 52 Rest of the World Oncology Biosimilars Market Value Share, by Country, 2017 and 2025 

Fig. 53 Rest of the World Oncology Biosimilars, Market Attractiveness, by Country, 2017–2025

Fig. 54 Rest of the World Oncology Biosimilars Market Value Share, by Drug Class, 2017 and 2025

Fig. 55 Rest of the World Oncology Biosimilars Market Attractiveness, by Drug Class, 2017–2025

Fig. 56 Rest of the World Oncology Biosimilars Market Value Share, by Disease Indication, 2017 and 2025

Fig. 57 Rest of the World Oncology Biosimilars Market Attractiveness, by Disease Indication, 2017–2025

Fig. 58 Rest of the World Oncology Biosimilars Market Value Share, by Distribution Channel, 2017 and 2025

Fig. 59 Rest of the World Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2017–2025

Fig. 60 Global Oncology Biosimilars Market Share, by Company, 2016 

Fig. 61 Breakdown of Net Sales of Sandoz International GmbH (A Novartis Division), by Franchise, 2016 (%)

Fig. 62 Revenue (US$ Bn) & Y-o-Y Growth (%) of Sandoz International GmbH (A Novartis Division), 2013–2016

Fig. 63 Breakdown of Net Sales of Pfizer, Inc., by Region, 2016 (%)

Fig. 64 Revenue (US$ Bn) & Y-o-Y Growth (%) of Pfizer, Inc., 2013–2016

Fig. 65 Breakdown of Net Sales of Celltrion Inc., by Business Segments , 2016

Fig. 66 Revenue (US$ Mn) & Y-o-Y Growth (%) of Celltrion Inc., 2013–2016

Fig. 67 Breakdown of Net Sales of Dr. Reddy’s Laboratories Ltd., by Business Segments, 2016 (%)

Fig. 68 Revenue (US$ Bn) & Y-o-Y Growth (%) of Dr. Reddy’s Laboratories Ltd., 2013–2016

Fig. 69 Breakdown of Net Sales of Biocon, by Business Segments, 2016 (%)

Fig. 70 Revenue (US$ Mn) & Y-o-Y Growth (%) of Biocon, 2013–2016

Fig. 71 Breakdown of Net Sales of Teva Pharmaceutical Industries Ltd., by Business Segments, 2016 (%)

Fig. 72 Revenue (US$ Bn) & Y-o-Y Growth (%) of Teva Pharmaceutical Industries Ltd., 2013–2016

Fig. 73 Breakdown of Net Sales of STADA Arzneimittel AG, by Business Segments, 2016 (%)

Fig. 74 Revenue (US$ Bn) & Y-o-Y Growth (%) of STADA Arzneimittel AG, 2013–2016

Fig. 75 Revenue (US$ Mn) & Y-o-Y Growth (%) of Intas Pharmaceuticals Ltd., 2013–2016

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *